Elanco Animal Health (NYSE:ELAN) Updates FY 2025 Earnings Guidance

Elanco Animal Health (NYSE:ELAN) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 0.800-0.860 for the period, compared to the consensus earnings per share estimate of 0.900. The company issued revenue guidance of $4.4 billion-$4.5 billion, compared to the consensus revenue estimate of $4.5 billion. Elanco Animal Health also updated its FY25 guidance to $0.80-$0.86 EPS.

Elanco Animal Health Trading Down 2.5 %

Shares of Elanco Animal Health stock traded down $0.28 during trading on Thursday, hitting $10.86. The company’s stock had a trading volume of 1,613,707 shares, compared to its average volume of 4,851,213. The stock has a 50-day moving average price of $11.74 and a two-hundred day moving average price of $13.06. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31. The stock has a market cap of $5.37 billion, a price-to-earnings ratio of 27.16, a price-to-earnings-growth ratio of 2.50 and a beta of 1.42. Elanco Animal Health has a 52 week low of $10.20 and a 52 week high of $18.80.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings data on Tuesday, February 25th. The company reported $0.14 EPS for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.01). The firm had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.01 billion. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The company’s revenue was down 1.4% on a year-over-year basis. During the same period last year, the business posted $0.08 EPS. Equities research analysts anticipate that Elanco Animal Health will post 0.91 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Leerink Partnrs raised Elanco Animal Health to a “hold” rating in a report on Monday, December 2nd. Stifel Nicolaus reduced their target price on shares of Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating on the stock in a report on Friday, February 21st. Morgan Stanley lowered their price objective on shares of Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating for the company in a research note on Wednesday. Leerink Partners started coverage on Elanco Animal Health in a research note on Monday, December 2nd. They issued a “market perform” rating and a $14.00 target price for the company. Finally, Barclays cut their price target on Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating on the stock in a research note on Wednesday. One analyst has rated the stock with a sell rating, four have assigned a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $15.57.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.